News | July 08, 2014

NorthStar Medical Radioisotopes Signs Pledge to Meet Requirements of Comprehensive Nuclear-Test-Ban Treaty Organization

July 8, 2014 — NorthStar Medical Radioisotopes LLC has signed a pledge with the Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO), designed to help the CTBTO detect nuclear testing.

In signing the Radioxenon Emissions Pledge, NorthStar stated that its production of the medical radioisotope molybdenum-99 (Mo-99) does not result in the emission of radioxenon, a radioactive noble gas. Based in Madison, Wis., NorthStar is one of only six producers of medical radioisotopes to have signed the pledge.

Radioxenon is one of the products measured by the CTBTO in its effort to detect nuclear testing. It also, however, may be emitted during the peaceful production of radioisotopes used in medical diagnostic imaging. Readings from both events look similar, making it more difficult for the CTBTO to identify potentially dangerous activities.

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope in medical diagnostic imaging. Currently, nearly all Mo-99 is generated using highly enriched uranium (HEU) and a fission-based process. NorthStar is pursuing two non-uranium- and non-fission-based, production processes that would help establish a reliable domestic source of Mo-99. Neither process results in the emission of radioxenon and both generate only a benign waste stream.

“The CTBTO’s work in minimizing radioxenon gas emissions is extremely important to the world community,” said NorthStar president and CEO George P. Messina. “We are pleased that our technology will help the world’s nuclear test-ban monitors focus on detecting nuclear explosions. Signing this CTBTO pledge is consistent with our effort to minimize our waste footprint by virtue of our unique, non-uranium, non-fission processes which produce no real waste by-products of consequence.”

“I welcome the pledge of NorthStar Medical Radioisotopes,” CTBTO executive secretary Lassina Zerbo said. “NorthStar is the sixth producer to cooperate with the CTBTO in our efforts to reduce the effects of radioactive releases on the detection of nuclear tests. The CTBTO will remain engaged with all medical isotope producers to mitigate xenon emissions for test-ban verification.”

For more information: www.northstarnm.com, www.ctbto.org

Related Content

PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Radiology Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Overlay Init